活性药物成分 (API) 的允许每日暴露 (PDE) 值的比较 - 强有力的方法的证据
Claudia Sehner1, Tanja Bernier2, Kamila Blum3
1Boehringer Ingelheim Pharma GmbH & Co. KG, 88397, Biberach, Germany.
Regulatory toxicology and pharmacology : RTP
|May 23, 2024
概括
尽管缺乏官方清单,但活性药物成分 (API) 的允许每日暴露限值 (PDE) 在各公司之间显示了可接受的变化. 这项研究证实了用于控制共享制造设施中的交叉污染的PDE计算的稳定性.
科学领域:
- 制药制造业 制药制造业 制药制造业
- 药物安全和风险评估.
背景情况:
- 允许的每日暴露限值 (PDE) 对于防止共享制药生产设施的交叉污染至关重要.
- 目前,没有官方的全球PDE列表存在,需要每个公司单独计算.
- 现有的指导方针允许PDE设置在定义范围内的公司间变化.
研究的目的:
- 评估活性药物成分 (API) 的PDE计算的稳定性和公司间一致性.
- 确定导致不同制药公司PDE设置变化的因素.
主要方法:
- 收集并比较了五种已上市的APIs的PDE数据:阿姆洛迪平,酸,甲福尔,吗啡和奥梅普拉.
- 分析了出发点 (POD) 选择和调整因子 (AF) 的变化.
- 研究了数据可用性,路线对路线外推和专家判断对PDE值的影响.
主要成果:
- 对所有测试的API来说,计算的PDE的变化在可接受范围内 (低于10倍).
- 吗啡表现出最高的变化,主要是由于不同的POD和AF.
- 影响PDE变化的关键因素包括数据可用性,POD/AF选择,路线推断和公司政策.
结论:
- 用于确定PDE的方法和计算是稳固的,科学上是合理的.
- 提供了协调整个制药行业的PDE计算方法的建议,以确保一致的药物安全标准.
相关概念视频
Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Pharmacovigilance
825
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
825
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K


